Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
cc-220 (1 trial)
Multiple Myeloma (Phase 2)
Neoplasms, Plasma Cell (Phase 2)
Trials (1 total)
Trial APIs (1 total)